Outcomes and costs of treatment with risperidone in adult and elderly patients: The Delta patient using risperidone study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 7-8, 2002, Pages 1313-1318

  Loonen, Anton J M ^a   Loos, Jacques C M ^a   Van Zonneveld, Theodora H ^a  

^a Delta Psychiatrisch Ziekenhuis   (Netherlands)

Author keywords

Costs of treatment; Elderly; Indications; Risperidone

Indexed keywords

RISPERIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; ELDERLY CARE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT CARE; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DRUG COSTS; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0036890003     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00295-6     Document Type: Article

References (9)

1. Cunningham Owens D.G. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. 1999;Cambridge Univ. Press, Cambridge.
2. Jeste D.V. Tardive dyskinesia in older patients. J. Clin. Psychiatry. 61(Suppl. 4):2000;27-32.
3. Jeste D.V., Caligiuri M.P., Paulsen J.S., Heaton R.K., Lacro J.P., Harris M.J., Bailey A., Fell R.L., McAdams L.A. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry. 52:1995;756-765.
4. Jeste D.V., Lacro J.P., Palmer B., Rockwell E., Harris M.J., Caligiuri M.P. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am. J. Psychiatry. 156:1999;309-311.
5. Jeste D.V., Lacro J.P., Bailey A., Rockwell E., Harris M.J., Caligiuri M.P. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc. 47:1999;716-719.
6. Jeste D.V., Okamoto A., Napolitano J., Kane J.M., Martinez R.A. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am. J. Psychiatry. 157:2000;1150-1155.
7. Kasper S., Rosillon D., Duchesne I. RODOS investigator group Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int. Clin. Psychopharmacol. 16:2001;179-187.
8. Kasper S., Jones M., Duchesne I. RODOS investigator group Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int. Clin. Psychopharmacol. 16:2001;189-196.
9. Tamminga C.A., Woerner M.G. Clinical course and cellular pathology of tardive dyskinesia. Davis K.L., Charney D., Coyle J.T., Nemeroff Ch. Neuropsychopharmacology: The Fifth Generation of Progress. 2002;1831-1841 Lippincott Wiliams & Wilkins, Philadelphia.